SBE-β-CD|cas 182410-00-0|DC Chemicals

SBE-β-CD|cas 182410-00-0|DC Chemicals

SBE-β-CD (Sulfobutylether-β-Cyclodextrin; Captisol) is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs; Captisol is the trademark of SBE-β-CD registered by Ligand Pharmaceuticals.

IC50 value:

Target: Drug adjuvant

SBE-β-CD is a unique reproducible mixture of polyanionic β-cyclodextrin derivatives in which a sodium sulfonate salt is tethered to the lipophilic cyclodextrin cavity by a butyl ether group, or sulfobutylether (SBE).

Product Name: SBE-β-CD|Cat No: DC9546|Cas: 182410-00-0|Molecule Formular: C50H84Na2O41S2|Molecule Weight: 1451.287|Other names: SBE-β-CD

SBE-β-CD (Sulfobutylether-β-Cyclodextrin) is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.
SBE-β-CD is a unique reproducible mixture of polyanionic β-cyclodextrin derivatives in which a sodium sulfonate salt is tethered to the lipophilic cyclodextrin cavity by a butyl ether group, or sulfobutylether (SBE). The sulfobutyl ether (SBE) substituent is introduced at the 2, 3, and 6 positions in one or more of the glucopyranose units in the cyclodextrin structure. The introduction of SBE substituents onto the β-cyclodextrin can produce preparations with different overall average degrees of substitution due to the proportion of multiple species present with different degrees of substitution, theoretically from 1 to 21 sites for substitution. SBE-β-CD, with on average 7 such SBE substituents per β-cyclodextrin, introduced by way of a reproducible patent-protected process, was chosen as the cyclodextrin preparation with the most desirable safety profile and drug association properties.

For research only, not for human use!